Evergreen Youth Secrets
  • Health News
  • Health Care
  • Staying Healthy
  • Beauty Advices
  • Health News
  • Health Care
  • Staying Healthy
  • Beauty Advices
No Result
View All Result
Evergreen Youth Secrets
No Result
View All Result
Home Health Care

Eli Lilly’s weight loss drug dramatically cuts risk of diabetes, company says

by
August 21, 2024
in Health Care
0
Eli Lilly’s weight loss drug dramatically cuts risk of diabetes, company says

Eli Lilly’s antidiabetic medication Zepbound cuts the risk of developing Type 2 diabetes by 94 percent in prediabetic adults and those who are overweight or obese, the company said Tuesday.  

Prediabetic and overweight adults who took part in a Phase 3 trial study experienced a significantly reduced risk of progressing to Type 2 diabetes after receiving weekly injections of the medication’s main ingredient tirzepatide over three years compared to those who received a placebo, the company said in a release.  

On top of this, adults who received injections with tirzepatide lost weight over their treatment period.  

Adults who took 15 mg of tirzepatide — the highest dosage anyone received as part of the study — lost about 23 percent of their body weight by the end of treatment compared to those on the placebo who lost an average of about 2 percent of their body weight.  

“The data reinforce the potential clinical benefits of long-term therapy for people living with obesity and pre-diabetes,” said Jeff Emmick, senior vice president of product development at Eli Lilly.  

Early results of a late-stage trial, “SURMOUNT-1,” were published in the New England Journal of Medicine in 2022. Those results helped the drug receive its Food and Drug Administration approval for weight loss last year.  

Eli Lilly submitted data for tirzepatide as a treatment for moderate-to-severe obstructive sleep apnea and obesity to the U.S. Food and Drug Administration earlier this year and plans to submit data on the drug’s use for heart failure later this year, the company said in the release.

In the release, Eli Lilly said the overall “tolerability” of tirzepatide in the Phase 3 study was consistent with the primary results of the SURMOUNT-1 study, with the most frequently reported adverse effects being mild to moderate nausea, diarrhea, constipation and vomiting.  

Previous Post

Gwen Walz shares fertility treatment she and her husband chose to have children

Next Post

Harris blasts Trump for saying he has ‘no regrets’ about end of Roe v. Wade

Next Post
Harris blasts Trump for saying he has ‘no regrets’ about end of Roe v. Wade

Harris blasts Trump for saying he has 'no regrets' about end of Roe v. Wade

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

    Popular News

    Spanberger hits Earle-Sears over health care, education in new ad

    Spanberger hits Earle-Sears over health care, education in new ad

    September 22, 2025
    Trump administration halts government hunger report

    Trump administration halts government hunger report

    September 22, 2025
    Former acting CDC director says he ‘can’t look to’ center for trusted info 

    Former acting CDC director says he ‘can’t look to’ center for trusted info 

    September 21, 2025

    Trending

    Humans may be inhaling 100 times more microplastics than previously assumed, scientists warn

    Humans may be inhaling 100 times more microplastics than previously assumed, scientists warn

    July 30, 2025
    Bird flu virus detected in raw milk in California

    Bird flu virus detected in raw milk in California

    November 26, 2024
    Harris, Trump clash over future of ObamaCare

    Harris, Trump clash over future of ObamaCare

    October 24, 2024
    Daily GLP-1 pill effective for diabetes and obesity, Eli Lilly says

    Daily GLP-1 pill effective for diabetes and obesity, Eli Lilly says

    April 17, 2025

    Recent News

    Spanberger hits Earle-Sears over health care, education in new ad

    Spanberger hits Earle-Sears over health care, education in new ad

    September 22, 2025
    Trump administration halts government hunger report

    Trump administration halts government hunger report

    September 22, 2025

    Popular News

    • Spanberger hits Earle-Sears over health care, education in new ad
    • Trump administration halts government hunger report

    About Evergreen Youth Secrets

    • Contact us
    • Privacy Policy
    • Terms & Conditions
    • Email Whitelisting

    Copyright © 2025 Evergreenyouthsecrets.com. All Rights Reserved.

    No Result
    View All Result
    • Health News
    • Health Care
    • Staying Healthy
    • Beauty Advices

    Copyright © 2025 Evergreenyouthsecrets.com. All Rights Reserved.